Clinical trial
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
NCT00373113 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00373113 |
|---|---|
| Title | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine |
| Official title | Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Capecitabine, Sunitinib malate |
| Enrollment | 482 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Jun 1, 2011 |
| First posted | Sep 7, 2006 |
| Last update posted | Jun 25, 2012 |
| Countries | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, France, Germany, Hong Kong, India, Italy and 11 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: